mRNA technology, as a new generation of vaccine manufacturing technology, continues to break through and expand its applications in the field of human infectious diseases. Compared to traditional attenuated/inactivated virus vaccines and subunit protein adjuvant vaccines, mRNA vaccines offer advantages such as lower development costs, shorter development cycles, higher safety, simpler processes, and stronger efficacy. Additionally, the natural adjuvant effect of mRNA vaccines can stimulate robust cellular immunity, leading to significant preventive effects against many infectious diseases. Moreover, mRNA vaccines are particularly suitable for developing multivalent vaccines, which can simplify vaccination procedures and reduce costs. They can serve as an ideal choice for rapid development of vaccines for unmet needs in animal infectious diseases or for rapid technological iterations, such as developing multivalent vaccines or improving protection rates for existing animal infectious disease vaccines. However, the application of mRNA technology in the veterinary field is limited by the stability and comprehensive cost of mRNA vaccine products.
EnoBio provides comprehensive, proprietary intellectual property technology services from antigen design to clinical sample production and regulatory submission. Clients can choose from a complete integrated solution or individual modules/technical solutions according to their specific needs, including AI-assisted antigen protein design, multi-antigen mRNA design and synthesis, mRNA-LNP lyophilization technology (leading global nanomedicine thermal stability technology1), immunostimulatory cap analogs, targeted LNP delivery systems, and immunostimulatory UTR and poly A tails. Leveraging proprietary intellectual property technologies, critical raw materials, and research and development production equipment supply chains, EnoBio can not only address the stability and comprehensive cost challenges of animal mRNA vaccine products but also meet various demands for the development of animal vaccines with full intellectual property control.
